Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN 3.9% rapamycin anhydrous gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania Show more

125 Strafford Avenue, Wayne, PA, 19087, United States

Biotechnology
Healthcare
Start AI Chat

Market Cap

1.88B

52 Wk Range

$18.23 - $151.18

Previous Close

$134.39

Open

$132.14

Volume

92,590

Day Range

$130.50 - $138.05

Enterprise Value

1.813B

Cash

63.57M

Avg Qtr Burn

-7.878M

Insider Ownership

19.92%

Institutional Own.

80.59%

Qtr Updated

09/30/25